Manish Kohli, Director and Physician Scientist Training Program University of Utah Health, shared on LinkedIn:
“The prostate cancer genome is no longer the limit for liquid biopsies, as we now can probe the proteome too in plasma using NGS approaches which we report using Olink Proteomics Limited and Alamar Biosciences. Proximity extension and Ligation approaches.
Most cancer drugs act on aberrant or overexpressed proteins, so we applied a plasma proteomics liquid biopsy approach across different states of prostate cancer progression.
Our aim was to find both prognostic proteins in metastatic castration resistant prostate cancer (mCRPC) as well as identify potentially druggable overexpressed tumor-associated proteins in patients with mCRPC.
Overexpressed protein candidates could be drug targets which were checked for a pharmacologically active drug–target interaction listed in DrugBank.
In mCRPC we find that syndecan-1 (CD138), NECTIN4, GDF15 , NECTIN2, HMOX2, IGFBP2 and other epithelial-mesenchymal transition proteins (EMT) are relevant to survival and several are potentially targetable too as several of these are overexpressed in plasma and metastatic mCRPC tissue too.
The heterogeneity of multiple overexpressed mCRPC prognostic proteins linked to poor prognosis was folded into a composite prognostic score that gives a survival readout in mCRPC, using a survival nomogram.
This real world dataset needs prospective validation, but remains unique as a first report using a liquid biopsy prostate cancer proteomics approach.
I’m grateful to the many investigators who made this exciting team-science project possible.”
Title: Plasma Proteome Profiles in Progressive Prostate Cancer States and Development of Composite Prognostic Stratification scores in Metastatic Castration-Resistant Prostate Cancer
Authors: Muhammad Zaki Fadlullah, Rafael Jimenez, Claire Hanson, Rebekah Gutowski, Anushka Shankar, Jennifer Lloyd, Jonathan David Tward, Benjamin Haaland, Liang Wang, Aik-Choon Tan, Manish Kohli
Read the Full Article.
You can also read: 10 Prostate Cancer Trials to Watch at ESMO 2026
